Skip to main content
Arbutus Biopharma Corp logo

Arbutus Biopharma Corp — Investor Relations & Filings

Ticker · ABUS ISIN · CA03879J1003 US Manufacturing
Open in API
Filings indexed 1,013 across all filing types
Latest filing 2024-11-14 Major Shareholding Noti…
Country US United States of America
Listing US ABUS

About Arbutus Biopharma Corp

https://www.arbutusbio.com/

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company focused on developing therapeutics for viral diseases, with a primary emphasis on creating a functional cure for chronic Hepatitis B virus (cHBV) infection. The company's strategy involves developing combination regimens that utilize multiple agents with complementary mechanisms of action. This approach aims to suppress viral replication, reduce viral antigens, and reawaken the host's immune response. A key candidate in its pipeline is imdusiran, an RNA interference (RNAi) therapeutic. Arbutus leverages its expertise in virology and drug delivery systems to advance its portfolio of clinical assets for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2024
Major Shareholding Notification
2024-11-14 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC by Arbutus Biopharma Corporation. It is a registration statement under the Securities Act of 1933 for the purpose of registering securities for sale to the public. The text includes details about the registration process, securities description, use of proceeds, risk factors, and forward-looking statements. It is not a financial report, earnings release, or management discussion. It is a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual registration statement, not just an announcement of a report.
2024-11-06 English
10-Q
Interim / Quarterly Report Q3 2024
2024-11-06 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions Item 2.02, which is "Results of Operations and Financial Condition," indicating a press release of quarterly financial results for the third quarter ended September 30, 2024. It also references an updated corporate presentation filed as an exhibit. The document itself is a short current report (3637 characters) that includes a press release and presentation as exhibits but does not contain the full financial statements or detailed financial analysis itself. According to the rules, such a document announcing financial results and including a press release is classified as an Earnings Release (ER). The presence of a corporate presentation as an exhibit does not change the primary classification. Therefore, the filing type is ER with high confidence.
2024-11-06 English
FORM 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes an Item 8.01 'Other Events' describing a press release about clinical data presentations, and Item 9.01 referencing exhibits including the press release. The document length is 3604 characters, which is relatively short and primarily serves as an announcement rather than a detailed report. There are no financial statements or substantive financial data included. The document is not an annual or quarterly report, nor is it a transcript, audit report, or other specific report type. It is a regulatory filing announcing an event and attaching a press release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other categories.
2024-10-15 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated October 11, 2024. The key content is the announcement of the retirement of a Chief Scientific Officer and an amendment to his employment agreement. This relates to changes in senior management. There are no financial statements or detailed financial data presented, and the document is not an earnings release, annual report, or other financial report. The primary focus is on management changes, specifically the departure of a director/officer and related employment agreement amendment. Therefore, the document fits the category of Board/Management Information (MANG). The document length is 4515 characters, which is consistent with a typical 8-K management change filing. Confidence is high due to clear identification of management change and no conflicting content.
2024-10-11 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.